Using the new HPV vaccines in clinical practice

Lea E Widdice; Jessica A Kahn

doi:10.3949/ccjm.73.10.929

Using the new HPV vaccines in clinical practice

Cleve Clin J Med. 2006 Oct;73(10):929-35. doi: 10.3949/ccjm.73.10.929.

Authors

Lea E Widdice¹, Jessica A Kahn

Affiliation

¹ Division of Adolescent Medicine, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA. [email protected]

PMID: 17044318
DOI: 10.3949/ccjm.73.10.929

Abstract

Gardasil, a vaccine against human papillomavirus (HPV), recently became available in the United States for use in girls and women 9 to 26 years of age. A second HPV vaccine, Cervarix, is under development. These vaccines constitute the most significant development in cervical cancer prevention in the last 60 years, having the potential to reduce the incidence of cervical cancer by up to 70%

Publication types

Review

MeSH terms

Adolescent
Adult
Child
Condylomata Acuminata / prevention & control
Condylomata Acuminata / virology
Female
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Humans
Papillomaviridae / immunology*
Papillomavirus Infections / epidemiology
Papillomavirus Infections / prevention & control*
Papillomavirus Infections / virology
Papillomavirus Vaccines / administration & dosage*
Treatment Outcome
Uterine Cervical Neoplasms / prevention & control
Uterine Cervical Neoplasms / virology
Viral Vaccines / administration & dosage*

Substances

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Papillomavirus Vaccines
Viral Vaccines